Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
ImmunoGen, Inc. (IMGN)
|
Add to portfolio |
|
|
|
| Price: |
$7.48
| | Metrics |
| OS: |
226.0
|
M
| |
-103
|
% ROE
|
| Market cap: |
$1.69
|
B
| |
|
|
|
Net cash:
|
$275
|
M
| |
$1.22
|
per share
|
|
EV:
|
$1.42
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($151)
|
M
| |
|
|
|
EBIT
|
($153)
|
M
| |
|
|
| EPS |
($0.70)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Jun-30-16 |
| Revenues | 108.8 | 69.9 | 132.3 | 82.3 | 53.4 | 115.4 | 0.0 | 60.0 |
| Revenue growth | 55.7% | -47.2% | 60.8% | 53.9% | -53.7% | 237308.5% | | -29.9% |
| Cost of goods sold | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 108.6 | 69.9 | 132.3 | 82.3 | 53.4 | 115.4 | 0.0 | 60.0 |
| Gross margin | 99.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 116.1 | 43.8 | 38.6 | | | | | |
| Research and development | 213.4 | 151.1 | 114.6 | 114.5 | 174.5 | 139.7 | | 148.1 |
| General and administrative | | | | 38.5 | 36.7 | 33.9 | 0.0 | 36.9 |
| EBIT | -220.9 | -125.1 | -20.9 | -70.7 | -157.8 | -58.2 | -0.1 | -125.0 |
| EBIT margin | -203.1% | -179.0% | -15.8% | -86.0% | -295.2% | -50.4% | -269.8% | -208.3% |
| Pre-tax income | -221.7 | -139.3 | -44.4 | -104.1 | -168.8 | -96.0 | -0.2 | -144.8 |
| Income taxes | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -222.9 | -139.3 | -44.4 | -104.1 | -168.8 | -96.0 | -0.2 | -144.8 |
| Net margin | -204.9% | -199.4% | -33.5% | -126.6% | -315.9% | -83.2% | -322.3% | -241.4% |
| |
| Diluted EPS | ($0.88) | ($0.68) | ($0.25) | ($0.70) | ($1.21) | ($0.98) | ($1.80) | ($1.67) |
| Shares outstanding (diluted) | 253.6 | 206.1 | 176.2 | 148.3 | 139.9 | 98.1 | 0.1 | 87.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|